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Purpose: To compare the effect of ranibizumab treatment versus photodynamic therapy (PDT) on single-stranded DNA
damage in circulating leukocytes in patients with exudative age-related macular degeneration (AMD).
Methods: A comparative quantification of single-stranded DNA breaks was performed in circulating leukocytes of AMD
patients before and 30 min, 45 min, 60 min, and 24 h after two different modes of therapy: a) PDT; and b) intravitreal
ranibizumab injection. DNA breaks lead to smaller pieces of DNA, which in an electrical field, migrate out of the nucleus
forming a tail. Damage of an individual cell was quantified as a comet tail moment. The proportion of non-zero values
compared to the total number of observations was referred to as “amount of DNA damage” expressed in arbitrary units
(AU). Comparisons between time points and study groups were assessed using a linear mixed-effect model.
Results: PDT induced an increase in the amount of single-stranded DNA damage in the circulating leukocytes from 0.2
AU (before treatment) to 0.53 AU (30 min after treatment). This increase was significant (p=0.004). In contrast, after
ranibizumab treatment, the DNA damage in the circulating leukocytes remained unchanged.
Conclusions: PDT purposely induces a local oxidative stress to damage the newly formed vessels. Our results indicate
an additional systemic oxidative stress, apparent as amount of single-stranded DNA damage in the circulating leukocytes,
for at least 30 min after treatment.
Age-related macular degeneration (AMD) is a leading
cause of irreversible blindness [1,2]. The overall prevalence
of advanced AMD is projected to increase by about 50% by
the year 2020 [3]. One important factor in the pathogenesis is
oxidative stress [4-6], which is molecular damage (including
DNA) by reactive oxygen species [7]. DNA damage can occur
as  double-strand  breaks,  which  result  from  damages  in
opposite strands of the DNA helix, or as single–strand breaks,
which result when only one of the two strands of a double
helix has a defect [8]. The amount of DNA damage in the
human body depends on cell type, cell age, patient DNA age,
repair capacity, and on exogenous factors such as oxidative
stress [9-11]. Increased DNA damage has been demonstrated
in  other  ocular  pathologies,  such  as  glaucoma,  where
oxidative damage also plays a role [12,13].
Photodynamic therapy (PDT) was a common therapy for
exudative AMD until it was replaced largely by intravitreal
application  of  vascular  endothelial  growth  factor  (VEGF)
inhibitors such as ranibizumab [14]. In PDT, a light-sensitive
dye, verteporfin, is injected intravenously. As it is bound to
low density lipoprotein (LDL), it binds predominantly to cells
with high metabolic activity such as endothelial cells of newly
formed vessels. The pathological tissue is purposely damaged
with  laser  light,  exciting  the  photosensitizer.  The
photosensitizer  transfers  energy  to  a  neighboring  oxygen
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molecule,  turning  it  into  singlet  oxygen,  which  induces
oxidative damage to newly formed vessels.
Using PDT we purposely induced local oxidative stress.
We tested the hypothesis of an additional systemic oxidative
stress as a side effect of treatment. We therefore compared the
effect of PDT versus ranibizumab treatment on the amount of
single-stranded DNA damage in circulating leukocytes.
METHODS
Study design: Patients with exudative AMD were recruited
from the University Eye Clinic Basel between January 2006
and September 2007. Ethical approval was obtained from the
local medical ethics committee, and written informed consent
was received from all participants before entry into the study.
The study was designed and conducted in accordance with the
tenets  of  Declaration  of  Helsinki,  and  12  patients  were
recruited.
All patients received a standard ophthalmic examination,
including  visual  acuity  measurement,  slit-lamp
biomicroscopy,  and  dilated  fundus  examination  that  was
performed by a retinal specialist. The diagnosis of exudative
AMD  was  based  on  ophthalmoscopic  and  fluorescein
angiographic findings. Inclusion criteria for patients were as
follows: 1) age of 50 years or older; 2) classic subfoveal
choroidal  neovascularization  (CNV)  on  fluorescein
angiography  in  one  eye;  3)  first-time  treatment  of  PDT.
Exclusion criteria included the following: 1) history of other
ocular or systemic disease (e.g., diabetes mellitus), smoking,
drug or alcohol abuse, trauma, infection, or inflammation; 2)
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1194macular lesions associated with other eye diseases, such as
degenerative myopia, angioid streaks, or any other retinal/
choroidal diseases.
Study treatment: After enrollment in the study, patients with
a  subfoveal  classic  CNV  were  randomly  selected  by  our
vitreoretinal specialist (T.J.) to receive either verteporfin PDT
or an intravitreal injection of 0.5 mg of ranimizumab. Only
one eye per patient was chosen as the study eye, and only the
study eye received treatment. If both eyes were eligible, the
eye with the better visual acuity was selected for treatment. In
addition, 20 ml blood samples were obtained by venipuncture
from all patients both before treatment and 30 min, 45 min,
60 min, and 24 h after treatment for analysis of DNA damage
by comet assay. Table 1 depicts the demographic data of the
two groups of patients.
PDT—Verteporfin (Dose: 6 mg/m2 body surface area ;
Infusion  rate:  3  ml/min)  was  infused  through  intravenous
access over a 10 min period. Approximately 15 min after the
start of the infusion, laser light of 689 nm was applied for 83
s to the CNV lesion through a fundus contact lens.
Intravitreal  ranibizumab  injection—Under  topical
anesthesia (tetracaine 1% eye drops) and sterile conditions,
0.5 mg of ranibizumab was injected with a 30 gauge needle
inserted 3.5 to 4 mm posterior to the limbus through the sclera
into the vitreous cavity behind the lens of the eye.
Comet assay analysis:
Isolation of leukocytes—Blood samples (20 ml) were
obtained by venipuncture from the two groups of patients and
collected in heparinized tubes. The leukocytes were isolated
using Ficoll-Histopaque gradients (Histopaque 1077; Sigma-
Aldrich, Zurich, Switzerland) [12]. Two ml of histopaque are
placed into 10 ml sterile centrifuge tubes and 5 ml of diluted
blood samples are carefully layered onto each histopaque
gradient. Gradients are centrifuged at 800x g for 15 min. The
leukocyte bands were removed from the interface between
plasma and the histopaque layers of each tube and collected
into one 50 ml tube. The total volume was brought to 50 ml
with  cold  Dulbecco’s  Modified  Eagle  Medium  (DMEM;
Gibco, Invitrogen, Basel, Switzerland). The cell suspension
was washed three times with DMEM, and the total number of
cells  was  determined.  Cells  were  finally  suspended  in
phosphate buffered saline (PBS 1X; 0.14 M NaCl, 0.003 M
KCl, 0.002 M K2HPO4, 0.01M Na2HPO4) and aliquoted into
Eppendorf tubes at 105 cells/tube. After centrifugation at 250x
g for 10 min, cell pellets were stored at −80 °C.
Gel  electrophoresis—Gel  electrophoresis  separates
damaged  DNA  from  undamaged  DNA.  This  method  has
previously been described in detail in the literature [15]. The
cells under study were embedded in agarose on a slide and
subjected to lysis followed by electrophoresis under specific
conditions.  DNA  is  negatively  charged,  in  particular,  in
alkaline conditions. When put in an electrical field, the intact
DNA was such a large molecule that it hardly moved. DNA
breaks,  however,  lead  to  smaller  pieces  of  DNA  which
migrated away from the intact DNA. The amount of migrated
DNA was the measure of the extent of DNA damage. To detect
DNA, the slides were stained with cyber-green and examined
by  fluorescence  microscopy  equipped  with  a  personal
computer based analysis system (Kinetic Imaging; Nikon,
Zürich, Switzerland), which enabled quantification of DNA
damage. Cells containing damaged DNA had the appearance
of a comet with a bright head (undamaged) and tail (damaged;
Figure 1).
Quantification of DNA damage—It is recommended by
manufacturers (Trevigen, Zürich, Switzerland) that 50 cells
on each slide be chosen at random for quantification of DNA
damage using the computer software. The tail moment is
defined as the product of the tail length and the fraction of
total DNA in the tail:
tail moment=tail length ×  % of DNA in the tail
This is calculated automatically by the comet assay computer
software system (Nikon) as an average for the 50 cells selected
for measurement.
Statistical analysis: The main parameter for the statistical
evaluation was the “tail moment.” As the parameter was zero-
inflated (had many zeros), its distribution was heavy-tailed.
Therefore,  the  assumption  for  regression  modeling  was
violated.  To  overcome  this  problem,  we  calculated  the
proportion of nonzero values compared to the total number of
observations for each blood sample of each participant. These
proportions were fairly good “log normal” distributed. To
TABLE 1. DEMOGRAPHIC DATA OF THE PATIENTS
Type of treatment PDT Ranibizumab p value
N 6 6
Age 66 (10.5) 67 (10.2) n.s.*
Male 50% 33% n.s.**
Female 50% 67% n.s.**
Age is expressed as mean and standard deviation (SD). The asterisk represents t-test,  and the double asterisk represents Fisher’s
exact test, and n.s. represents not significant. There were no significant differences in age or gender between the group of patients
treated with PDT and the one treated with ranibizumab.
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DNA damage.” Comparisons between time points and study
groups were assessed using a linear mixed-effect model as will
be described.
To explore the effect of time for PDT and ranibizumab,
we performed a linear mixed-effect model with fixed factor
“time” and random factor “subject” on the log-transformed
proportions.  This  model  allowed  comparisons  before
treatment with postoperative treatment at the various times of
30 min, 45 min, 60 min, and 24 h. Descriptive statistics and
corresponding box plots are reported in Table 2 and Figure 2.
A p-value <0.05 was considered significant. The p-values of
the statistical tests were interpreted in a purely exploratory
manner and were not adjusted for multiple comparisons. All
analyses were done using the statistical software R, version
7.1.
Figure 1. Photographs of cells analyzed by comet assay analysis. A:
Photograph A depicts intact cells (without tail) of a patient treated
with ranimizumab. B: Photograph B depicts cells of a patient 30 min
after treatment with PDT. Arrowhead points to a typical “comet”
with a bright head and tail.
RESULTS
Amount of DNA damage: Patients treated with PDT (n=6)
showed a significant increase in the amount of DNA damage
in the circulating leukocytes from 0.2 AU (before treatment)
to 0.53 AU (30 min after treatment) (p=0.004; Figure 2). At
all other postoperative times no significant differences in the
amount of comet tails in comparison to before treatment were
accounted  for.  In  the  ranibizumab-treated  group  (n=6),
however, there was a slight, yet not significant tendency for a
decrease in the DNA damage up to 45 min (see Table 2).
DISCUSSION
In this study we quantified the amount of DNA damage in
circulating leukocytes of patients with exudative AMD before
and 30 min, 45 min, 60 min, and 24 h after either PDT or
intravitreal ranibizumab injection. There was a significant
increase in DNA damage 30 min after treatment with PDT.
No  such  increase  in  DNA  damage  was  observed  after
intravitreal ranibizumab treatment.
DNA  damage  can  result  from  a  variety  of  factors
including ultraviolet light, X-rays, ionizing radiation, toxins,
chemicals,  or  reactive  oxygen  species  [16-22].  The  most
likely reason for a higher rate of DNA damage shortly after
PDT treatment is oxidative stress induced by the illumination
of a photosensitizer. Photosensitizers utilize energy from light
to  turn  ground  state  oxygen  (O2;  the  most  stable  state  of
oxygen) into reactive oxygen species [23,24]. In the ground
state, the last two electrons of the oxygen molecule are located
in  a  different  p*  antibonding  orbital.  These  two  unpaired
electrons have the same quantum spin number (they have
parallel  spins).  If  ground  state  oxygen  absorbs  sufficient
energy to reverse the spin of one of its unpaired electrons, the
two  unpaired  electrons  then  have  opposite  spins.  This
Figure  2.  Amount  of  DNA  damage  before  and  after  PDT  and
ranibizumab treatment. With the exception of columns marked pre,
all times are post treatment. PDT induced an increase in the amount
of single stranded DNA damage in the circulating leukocytes from
0.22AU (before treatment) to 0.53 AU (30 min after treatment).
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1196activated form of oxygen is called singlet oxygen (1O2) [25].
Singlet  oxygen  is  much  more  reactive  than  ground  state
oxygen and disrupts CNV [26,27]. Therefore, the neovascular
lesions are ultimately destroyed by an iatrogenic source of
oxidative stress. Paradoxically, oxidative stress, which plays
a key role in the pathogenesis of AMD [28], is used as a
treatment modality [14], and this, in turn, leads to a short-term
systemic oxidative stress.
The systemic oxidative stress observed 30 min after PDT
was short-term and transient in nature, rather than long-term.
Injury to DNA is minimized by systems that recognize and
correct the damage [29]. DNA breaks are therefore the result
of balance between the damaging events occurring in DNA
and the repair mechanisms reversing the damage to DNA
[30]. In our investigation we quantified single–stranded DNA
damage. This type of damage [31,32] is repaired at a faster
rate than double-stranded DNA damage. As PDT is used in
several medical fields, such as oncology [33,34], dermatology
[35-37] or cosmetic surgery [38], knowledge of a transient
systemic oxidative stress may eventually lead to the use of
systemic antioxidative treatment in combination with PDT.
The study design did not allow a differentiation as to how
much of the oxidative stress expressed as DNA damage was
due to laser radiation of the macula and how much was due to
environmental light reaching both the eye and the skin. It
would  have  been  interesting  to  compare  our  results  of
systemic oxidative stress in patients with exudative AMD to
those with dry AMD. Further investigations are needed.
Treatment with PDT requires intravenous administration
of verteporfin with maximum systemic exposure immediately
after perfusion. However, ranibizumab is administrated by
intravitreal injection, and systemic exposure after intravitreal
administration of a drug is dependent of its pharmacokinetics.
Ranibizumab is distributed rapidly to the retina after 6 to 24
h [39]. Moreover, serum concentrations of ranibizumab were
shown to be very low [39], reflecting wider distribution and
faster clearance when the drug reached the serum. Our results
support this investigation. Our quantitative analysis of DNA
breaks after 1 h and 24 h after treatment were not significantly
different  from  each  other,  showing  that  there  was  no
significant  systemic  oxidative  stress  after  ranibizumab
treatment. But even if serum concentrations of ranibizumab
were higher, we would still not expect an increase in systemic
oxidative  stress  after  treatment  with  a  recombinant,
humanized  monocloncal  Fab  fragment  that  neutralizes  all
active forms of VEGF- A [40]. Ranibizumab is thus not only
more effective [41], it probably also induces less systemic side
effects. In conclusion, PDT may lead to a transient systemic
oxidative stress as observed by a higher rate of DNA damage
after PDT treatment. Ranibizumab has no such side effects.
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